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design is the double-blind, placebo-controlled, randomized
trial. Intravenous medication, which needs reconstitution
by the attending clinician in an emergency situation, can
be challenging to incorporate into a suitably blinded study.
Discussion:We have developed a method of blindly reconsti-
tuting and administering fibrinogen concentrate (presented
as a lyophilized powder), where the placebo is normal saline.
Fibrinogen concentrate is increasingly being used early in
the treatment of major hemorrhage. Our methodology
was designed for a multicenter study investigating the role
of fibrinogen concentrate in the treatment of the coagulop-
athy associated with major obstetric hemorrhage. The
method has been verified by a stand-alone pharmaceutical
manufacturing unit with an investigational medicinal prod-
ucts license, and to date has successfully been applied 45
times in four study centers. There have been no difficulties
in reconstitution and no related adverse events reported.
Conclusion: We feel our method is simple to perform and
maintains blinding throughout, making it potentially suit-
able for use in other trials conducted in psychologically
high-pressure environments. Although fibrinogen concen-
trate was the focus of our study, it is likely that the method
is applicable to other lyophilized medication with limited
shelf life (e.g., antibiotics).  2016 The Authors. Published
by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).ly 2015; FINAL SUBMISSION RECEIVED: 11 Septem
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The double-blind placebo-controlled randomized trial is
the gold-standard trial design. It is therefore crucial that
in medicinal-based studies, the active drug or placebo
(investigative medicinal product [IMP]) is stored and
administered in a way that prevents the clinician involved
knowing what is being given to the patient. The adminis-
tration of intravenous IMP that has a limited shelf life
once reconstituted usually requires a pharmacist or clini-
cian who is not directly involved in the trial to mix the
product or provide a saline substitute in a covered sy-
ringe. This ensures adequate mixing and exclusion of
air in the syringe while maintaining blinding within the
trial to the clinician.
There are an increasing number of registered trials
where reconstitution of the IMP is required in the emer-
gency setting, and due to the trial design, researchers
may have to recruit out of hours. Depending on the fre-
quency of the intervention, itmay be possible to have ready
prepared IMPor employ staff to cover the out-of-hours ser-
vice, but if the IMP has a short shelf life oncemixed, or theber 2015;
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be very wasteful and be prohibitively expensive.
There are a number of registered trials where fibrin-
ogen concentrate (RiaSTAP, CSL Behring, Marburg,
Germany) is being compared to placebo (saline) in the
emergency setting of obstetric and traumatic hemor-
rhage (1–3). It is essential within these trial settings
that the IMP can be administered quickly, without
safety concerns, and without un-blinding. In the study,
fibrinogen concentrate vs. placebo for treatment of post-
partum hemorrhage: a multicenter, prospective, double-
blind, randomized control trial; Ref: 13/SS/0008
(ISRCTN4629339); recruitment has required that over
500 clinicians be trained to mix and administer the
IMP, but due to the rarity of the clinical situation, only
45 patients have been randomized over a 2-year period
(4). The end-point of the trial is the number of blood-
products used, and un-blinding could influence
decision-making and trial outcome. The mixing method
had to be easy to teach, easy to remember, and the final
product quick and easy to administer.DISCUSSION
Outline of Blinding Methodology (Detailed Description,
with Step-by-Step Guide, Appendix 1)
Fibrinogen concentrate is presented as a white hydrophil-
ic powder containing 1 g of human fibrinogen per glass
vial. It can be stored at room temperature (<25C) for
5 years. Manufacturer’s reconstitution instructions
recommend adding 50 mL of water for injection and
gently agitating for 5 to 10min (may require 15 min) until
the powder is fully reconstituted. The resulting solution
may vary in appearance from almost colorless to
yellowish, clear to slightly opalescent, but always looks
slightly viscous (5). In our experience, this process can
cause frothing, especially if a narrow-bore needle is
used to transfer the water and draw up the medication
in haste. Once reconstituted, it is stable at room tempera-
ture for 8 h. The placebo in our study was 0.9% saline for
injection, and although similar in volume, looks different
due to the clarity, viscosity, and the propensity of the
fibrinogen product to form bubbles. By covering the bot-
tles with cardboard jackets, using a series of wide-bore
decanting and drawing-up spikes, using black
(completely opaque) syringes and expelling air that was
drawn up into the syringe into a gelatin intravenous prod-
uct, we successfully designed a system that fulfilled the
requirements for the trial. The crucial final step of expel-
ling the air, which is inevitably drawn into the opaque sy-
ringe, by injecting into an inverted bag of gelatin for
intravenous use, ensured that all air has been safely
expelled and blinding was not lost.The mixing process was verified by the St Mary’s
Pharmaceutical Unit (SMPU), a stand-alone pharmaceu-
tical manufacturing unit with an investigational medici-
nal products license [MIA(IMP)]. They verified that by
decanting water under gravity through a wide-bore
double-ended spike into a bottle of fibrinogen concentrate
power and then leaving the contents of the bottle to stand
rather than be agitated as described in the manufacturer’s
insert, the fibrinogen concentrate had completely dis-
solved by the time the solution had been drawn into a
clear 50-mL syringe. This was repeated 16 times and
overseen by an SMPU pharmacist. SMPU also investi-
gated the perception of the force required to fill the
syringe with the mixed fibrinogen concentrate and the
perception of the force required to expel the air/bubbles
into the gelatin product. After covering the 50-mL
syringes, they concluded that there was no difference
between the reconstituted fibrinogen and saline. The pro-
cess was performed eight times for each solution.
To date, this mixing procedure has been performed
45 times across four centers. There have been no reported
problems.
Our method outlines a reliable method for mixing and
administering two dissimilar intravenous medications in
the setting of a randomized, placebo-controlled, double-
blinded study. It is simple to perform, making it suitable
for use in a psychologically high-pressure environment
and maintains blinding throughout.
Strengths
This method of reconstitution improves on current
guidelines. The use of wide-bore transfer devices and
dispensing pins enhances the procedure by speeding up
fluid transfer, reducing frothing, improving mixing, and
reducing the risk of needle-stick injury. The use of black
syringes is uncommon in clinical practice, but has worked
without safety concerns in this trial. A rapid method of
reconstituting fibrinogen has been described by Karri
et al. (6). In this method, 50 mL of sterile water was forc-
ibly injected into the bottle containing the fibrinogen
concentrate. The mixture was then vigorously shaken
for 30 s prior to being aspirated into a syringe. Despite
producing excess foaming, the dissolved fibrinogen solu-
tion was as effective at raising plasma fibrinogen levels as
fibrinogen solution prepared using the conventional
method. This protocol was not part of a blinded study,
so has limited application when the IMP is being drawn
into an opaque syringe.
Limitations
The method is robust if followed, however, there are
opportunities for un-blinding: handling or shaking the
Figure 1. Equipment required for the mixing process.
106 D. Bruynseels et al.covered bottle before the diluent is added can lead to
faintly audible rattling of the fibrinogen powder. To
prevent this, the method requires that the covered bottle
not be removed from the storage box until after the
diluent has been added. Removing or damaging the
cardboard jacket will make the contents visible, although
all the bottles used and unused are retained for inspectionFigure 2. 1) Mix the diluent and investigative medicinal
product (IMP) bottles. 2) Aspirate the mixed IMP into the
black syringe.
Figure 3. Expelling the air from the upturned syringe.and disposal by the study team, therefore, this would be
evident. If the air and bubbles from the black syringes
are expelled into fluid less viscous than gelatin, such as
normal saline, differences can be seen. If the content of
the syringe is deliberately or inadvertently expelled into
the air, the clinician may see a froth from the syringe
containing fibrinogen concentrate, which, when it dries,
leaves a tacky residue. This is impossible to prevent
entirely, but is warned against during training.
CONCLUSION
In the context of many blinded trials, developing a
reliable and simple method for mixing and administering
dissimilar intravenous study medication and placebo can
be challenging. In this study, there was the added pressure
of reproducing the method in an emergency setting,
which frequently occurs out of normal working hours.
To date, there have been no major difficulties or protocol
deviations associated with the mixing procedure.
Although this method describes the mixing of one
product, there has been interest from other groups who
want to design trials using fibrinogen concentrate in
emergency settings. Within the current study, the method
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tially be also applicable in open-label studies that do not
require the use of black syringes. The clinical applica-
bility of the method may also be assessed in the future.
There are also a number of trials proposed where, in an
emergency situation, the reconstitution and administra-
tion of lyophilized drugs, such as antibiotics, is required
(7). With suitable drug-specific testing, this basic mixing
and blinding procedure may also be considered in such
settings.REFERENCES
1. Copenhagen University Hospital, Denmark. Pilot randomized trial of
fibrinogen in trauma haemorrhage. Bethesda, MD: National Library
of Medicine (US). Available at: https://clinicaltrials.gov/show/
NCT02344069NLMIdentifier:NCT00004451.AccessedJune7, 2015.
2. Sunnybrook Health Sciences Centre, Toronto, Canada. Fibrinogen
in the initial Resuscitation of Severe Trauma (FiiRST). Bethesda,MD: National Library of Medicine (US). Available at: https://
clinicaltrials.gov/show/NCT02203968 NLM Identifier: NCT02
203968. Accessed June 7, 2015.
3. Laboratoire franc¸ais de Fractionnement et de Biotechnologies,
France. Fibrinogen in Haemorrhage of Delivery (FIDEL). Bethesda,
MD: National Library of Medicine (US). Available at: https://
clinicaltrials.gov/show/NCT02155725 NLM Identifier: NCT021
55725. Accessed June 7, 2015.
4. Aawar N, Alikhan R, Bruynseels D, et al. Fibrinogen concentrate
versus placebo for treatment of postpartum haemorrhage: study pro-
tocol for a randomised controlled trial. Trials 2015;16:169.
5. CSL Behring, Marburg, Germany. RiaSTAP summary of product
characteristics. Available at: http://www.mhra.gov.uk/Safety
information/Medicinesinformation/SPCandPILs/?prodName=RIA
STAP%201G%20POWDER%20FOR%20SOLUTION%20FOR%
20INJECTION%20OR%20INFUSION&subsName=HUMAN%20
FIBRINOGEN&pageID=SecondLevel. Accessed April 30, 2014.
6. Karri JV, Cardenas JC, Johansson PI, et al. In vitro efficacy of
RiaSTAP after rapid reconstitution. J Surg Res 2014;186:586–7.
7. The University of Queensland, Australia. Trial of meropenem
versus piperacillin-tazobactam on mortality and clinical response
(MERINO II). Bethesda, MD: National Library of Medicine (US).
Available at: https://clinicaltrials.gov/show/NCT02437045 NLM
Identifier: NCT02437045. Accessed June 7, 2015.
APPENDIX 1
DESCRIPTION OF EQUIPMENTAND METHODOLOGY
Equipment required for preparation of the investigative medicinal product (IMP) (Figure 1):
1. Covered bottle. 100-mL Glass bottle containing fibrinogen concentrate (RiaSTAP, CSL Behring, Marburg,
Germany), covered with cardboard jacket up to the stopper or an identical empty (placebo) bottle also covered.
The stoppers of both bottles were identical.
2. Diluent. Glass bottle containing 50 mL water for injection into fibrinogen concentrate or an identical bottle with
saline as the placebo (Fresenius Kabi, Bad Homberg, Germany). The label on these bottles was covered (though the
batch number on the neck was not), but because the contents and appearance of the bottles (including the stoppers)
were visually identical, no jackets were required.
3. Transfer device (Transfer Device, ref: 8500432, Fresenius Kabi, Bad Homberg, Germany.)
4. Dispensing pin (Dispensing pin with Luer lock Safsite valve, ref: 412006, B. Braun Medical, Melsungen,
Germany.)
5. Black syringe (Original-Perfusor Syringe 50-mL Luer Lock, ref: 8728828F, B. Braun Medical, Melsungen,
Germany.)
6. Needle (BD Microlance 3, 21G, ref: 304432, BD, Franklin Lakes, New Jersey.)
7. Gelofusine (Gelofusine Ecobag, 500 ml, B. Braun Medical, Melsungen, Germany.)
The IMP bottles were placed in a large partitioned box, which prevented their movement and were lined up with the
clear diluent bottles. All other equipment was provided in a consumables box. The boxes were stored at room temperature
(<25C as per manufacturers summary of product characteristics) (5).
Methodology for reconstitution of the IMP:
The number of bottles prepared depends on the study protocol.
1. Remove the covers from the injection ports of both the IMP and diluent bottles. The IMP bottle remains in the
partitioned box.
2. Insert one end of each transfer device into the required number of IMP bottles.
3. Invert the first diluent bottle and push onto the other end of the transfer device. (Figure 2) (1).
4. Repeat, depending on the number of IMP bottles required by the study protocol.
5. After 1 min, the diluent has drained, under gravity, into the covered bottles.
6. Remove and dispose of the used diluent bottles and transfer devices.
7. Pick up the IMP bottles in turn from the partitioned box and gently invert three times.
8. Place on work top and wait for 3 min.
Drawing the IMP into the black syringe for patient administration is now performed one syringe at a time:
9. Insert the dispensing pins into the IMP bottles.
10. Fully attach the black syringe to the Safsite Luer-lock valve of the dispensing pin.
11. Invert. Ensure the black syringe, dispensing pin and covered bottle are vertical (Figure 2) (2).
12. Fully withdraw the plunger on the black syringe.
13. Detach the dispensing pin and IMP bottle from the black syringe.
14. Attach the 21G needle to the black syringe.
15. Insert the needle into the Gelofusine ecobag injection port.
16. Hold the syringe and Gelofusine vertically.
17. Depress the plunger on the syringe, observing the air being expelled into the Gelofusine as bubbles (Figure 3).
18. When the bubbles stop and increased resistance to injection is felt, the air has been expelled.
19. Withdraw the syringe, detach and dispose of the needle.
20. The black syringe now contains 50 mL of fully dissolved fibrinogen solution or saline with no air and can be
injected.
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